Sugi Predict

Sugi Predict / Compounds / SCHEMBL2230132

SCHEMBL2230132

SCHEMBL2230132

O=C(O)CNC(=O)c1cccc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 2/20 0.61
▸ MMP3 P08254 1/20 0.61
▸ PLK1 P53350 1/20 0.59
▸ HPGD P15428 3/20 0.57
▸ PPARG P37231 1/20 0.57
▸ NR4A1 P22736 1/20 0.56
▸ NR4A2 P43354 1/20 0.56
▸ NR4A3 Q92570 1/20 0.56
▸ HDAC3 O15379 1/20 0.56
▸ HDAC4 P56524 1/20 0.56
▸ HDAC1 Q13547 1/20 0.56
▸ HDAC7 Q8WUI4 1/20 0.56
▸ HDAC2 Q92769 1/20 0.56
▸ HDAC10 Q969S8 1/20 0.56
▸ HDAC11 Q96DB2 1/20 0.56
▸ HDAC6 Q9UBN7 1/20 0.56
▸ HDAC9 Q9UKV0 1/20 0.56
▸ HDAC5 Q9UQL6 1/20 0.56
▸ NR1H4 Q96RI1 1/20 0.56
▸ KEAP1 Q14145 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7771334 0.85 HDAC8 (0.59) HDAC8MMP3PLK1HPGDPPARG
SCHEMBL18457265 0.85 PLK1 (0.62) HDAC8MMP3PLK1HPGDPPARG
SCHEMBL18457431 0.85 HDAC8 (0.59) HDAC8MMP3PLK1HPGDPPARG
SCHEMBL7771330 0.85 HDAC8 (0.59) HDAC8MMP3PLK1HPGDPPARG
SCHEMBL9830463 0.84 PPARG (0.58) HDAC8MMP3PLK1HPGDPPARG
SCHEMBL31448014 0.83 KEAP1 (0.62) KEAP1FTORAB9A
SCHEMBL27903143 0.83 HDAC2 (0.73) HDAC8MMP3PLK1HPGDHDAC3
SCHEMBL3792160 0.82 PLK1 (0.58) HDAC8MMP3PLK1HPGDHDAC3
SCHEMBL31060081 0.82 PLK1 (0.58) HDAC8MMP3PLK1HPGDHDAC3
SCHEMBL3796366 0.82 HDAC8 (0.56) HDAC8MMP3PLK1HPGDNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459363-B Fluorine substituted proliferation cell nuclear antigen inhibitor and preparation method and application thereof 安徽贝克制药股份有限公司 2024-12-17 — — CN claimed
CN-118546074-A Deuterated proliferation cell nuclear antigen inhibitor and preparation method and application thereof 安徽贝克制药股份有限公司 2024-08-27 — — CN claimed
CN-118459363-A Fluorine substituted proliferation cell nuclear antigen inhibitor and preparation method and application thereof 安徽贝克制药股份有限公司 2024-08-09 — — CN claimed
CN-117603081-A Preparation method of N- (2- ((2- (3-methoxyphenoxy) phenyl) amino) -2-acetoxy) -1-naphthylamine 沈阳药科大学 2024-02-27 — — CN claimed
US-20100056605-A1 OXIDATIVE DEGRADATION PRODUCTS OF ATORVASTATIN CALCIUM LEK PHARMACEUTICALS D.D. (SI) 2010-03-04 — — US claimed
US-4866197-A Production of N-((2-alkoxy-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)carbonyl)-N-methylglycine esters AMERICAN HOME PRODUCTS CORPORATION (US) 1989-09-12 — — US claimed
EP-0132994-B1 COMPOUNDS FOR LOWERING LIPID LEVELS AMERICAN HOME PRODUCTS CORPORATION (US) 1988-06-01 — — EP claimed
EP-0132994-A1 Compounds for lowering lipid levels AMERICAN HOME PRODUCTS CORPORATION (US) 1985-02-13 — — EP claimed
US-4492706-A Method of lowering lipid levels AMERICAN HOME PRODUCTS CORPORATION (US) 1985-01-08 — — US claimed
CN-118459363-B Fluorine substituted proliferation cell nuclear antigen inhibitor and preparation method and application thereof 安徽贝克制药股份有限公司 2024-12-17 — — CN disclosed
CN-118546074-A Deuterated proliferation cell nuclear antigen inhibitor and preparation method and application thereof 安徽贝克制药股份有限公司 2024-08-27 — — CN disclosed
CN-118459363-A Fluorine substituted proliferation cell nuclear antigen inhibitor and preparation method and application thereof 安徽贝克制药股份有限公司 2024-08-09 — — CN disclosed
CN-117603081-A Preparation method of N- (2- ((2- (3-methoxyphenoxy) phenyl) amino) -2-acetoxy) -1-naphthylamine 沈阳药科大学 2024-02-27 — — CN disclosed
US-11345656-B2 PCNA inhibitors CITY OF HOPE (US) 2022-05-31 — — US disclosed
US-4439617-A TREATING DIABETES, ENZYME INHIBITOR AYERST, MCKENNA & HARRISON INC. (CA) 1984-03-27 — — US disclosed
US-4391816-A ANTIDIABETIC AGENTS AYERST, MCKENNA & HARRISON INC. (CA) 1983-07-05 — — US disclosed
US-4391825-A ALDOSE REDUCTASE INHIBITORS, FOR TREATING DIABETIC COMPLICATIONS AYERST, MCKENNA & HARRISON INC. (CA) 1983-07-05 — — US disclosed
EP-0059596-A1 N-Naphthoylglycine derivatives AYERST, MCKENNA AND HARRISON INC. (CA) 1982-09-08 — — EP disclosed
EP-0059596-A1 N-Naphthoylglycine derivatives AYERST, MCKENNA AND HARRISON INC. (CA) 1982-09-08 — — EP disclosed
EP-0059596-A1 N-Naphthoylglycine derivatives AYERST, MCKENNA AND HARRISON INC. (CA) 1982-09-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056605-A1 OXIDATIVE DEGRADATION PRODUCTS OF ATORVASTATIN CALCIUM HMGCR, ORAI1, CYP11A1 HDAC8 2699/4885MMP3 3529/4885PLK1 2926/4885
US-11345656-B2 PCNA inhibitors PCNA, MKI67, PCLAF HDAC8 505/4885MMP3 2529/4885PLK1 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.